Latest News

Some of the news articles below may show only part of the news story. To view the full story, click on Read More below the story. 

  • February 26, 2019 3:40 PM | Deleted user

    February 26, 2019, International Continence Society  

    The 49th International Continence Society Annual Meeting will take place on 3-6 September 2019, in Gothenburg, Sweden. This will be a unique experience for all those treating continence and related issues.

    With abstract submission opening March 1, now is the time to take a significant role in the premium meeting in the field. Use the opportunity to:

    ·        Get exposure for your research

    ·        Present alongside the research and practice leaders

    ·        Receive constructive feedback

    ·        Contribute to advancing the treatment of LUTS, incontinence and pelvic floor disorders

    Prepare and submit your abstract by April 1, 2019.

    For more information, visit the ICS 2019 website: https://www.ics.org/2019



  • February 22, 2019 7:10 AM | Deleted user

    February 22, 2019, HealthDay News  

    An experimental drug has shown promise in extending the lives of women suffering from a particularly aggressive and deadly type of breast cancer, according to the results of a phase 2 trial. Right now, the standard treatment of chemotherapy for metastatic triple-negative breast cancer has not been very effective. That might change with the new drug, called sacituzumab govitecan, which combines an antibody with a chemotherapy drug to better target cancer cells.  

    Read more.

  • February 22, 2019 7:05 AM | Deleted user

    February 22, 2019, News Medical 

    New research recently published in the Journal of Clinical Microbiology suggests that the standard test used by the NHS — midstream urine culture (MSU) — may not be reliable enough to exclude a UTI in patients with LUTS. Thousands of women with UTIs experience chronic LUTS that dominates their lives. Despite spending months and years visiting hospitals and GP practices, the tests and treatments they receive still fail to resolve the problem. 

    Read more.

  • February 21, 2019 10:20 AM | Deleted user

    February 21, 2019, MedPage Today 

    The incidence of precancerous cervical lesions containing human papillomavirus (HPV) declined significantly from 2008 to 2014, as did the HPV strains that cause most cervical cancers, CDC investigators reported. 

    Read more.

  • February 20, 2019 10:19 AM | Deleted user

    February 20, 2019, MedPage Today 

    The goal of this study was to determine the safety and efficacy of umbilical cord blood (UCB) grafts using NiCord, a single cord blood unit expanded ex vivo with nicotinamide, and transplanted into patients with a variety of hematological malignancies after myeloablative conditioning. Researchers compared NiCord's activity to historical data on 146 closely-matched transplant patients from the Center for International Blood and Marrow Transplant Research (CIBMTR). 

    Read more.

  • February 20, 2019 10:17 AM | Deleted user

    February 20, 2019, HealthDay News 

    Younger U.S. women are suffering heart attacks at a higher rate now than 20 years ago — even while the picture has improved for younger men. Those are the key findings from a new study of four U.S. communities, in which researchers report the heart attack rate among women younger than 55 has steadily inched upward since 1995. In contrast, the rate dipped among men in that age group. 

    Read more.

  • February 20, 2019 10:16 AM | Deleted user

    February 20, 2019, HemOnc Tdoay  

    Women who have a family history of certain types of cancer should be screened to determine if they have an increased risk for BRCA1 or BRCA2 mutations, according to a draft recommendation from the U.S. Preventive Services Task Force. Women with an ethnicity or ancestry linked to these genetic mutations also should be screened.  

    Read more.


  • February 20, 2019 10:12 AM | Deleted user

    February 20, 2019, MedPage Today 

    Early screening for gestational diabetes was not linked with a decrease in the risk of adverse perinatal outcomes in a cohort of obese women, a researcher said here.

    Read more.

  • February 19, 2019 10:48 AM | Deleted user

    February 19, 2019, MedPage Today 

    Women who received non-opioid analgesia following cesarean delivery had a lower mean pain score than women who received opioids along with other pain medicine, a researcher said here.

    A small randomized trial found mean pain scores lower for women in the non-opioid group versus the opioid group at 2-4 weeks postpartum, meaning opioids for pain may be inferior (12.3 vs 15.9, respectively, adjusted mean difference 4.8, 95% CI -2.1 to 11.9), reported Jenifer Dinis, MD, of McGovern Medical School at the University of Texas, Health Science Center in Houston.

    Read more.
  • February 15, 2019 8:04 AM | Deleted user

    February 15, 2019, Medscape 

    The treatment of HER2-positive, early stage breast cancer has taken "one more step toward personalized medicine and reduced mortality" thanks to the results of the KATHERINE trial, according to Daniel Hayes, MD, a medical oncologist at the University of Michigan Rogel Cancer Center in Ann Arbor. He says the trial is a "game changer" for patients who have residual disease after initial drug treatment and surgery, in an editorial published online in the New England Journal of Medicine. 

    Read more.

Powered by Wild Apricot Membership Software